Cargando…

Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder

OBJECTIVE: To investigate the impact of regular cannabis use on long-term remission of mood symptoms in bipolar spectrum disorders. METHODS: The 24-month prospective observational study included patients (n=239) with bipolar I disorder and schizoaffective disorder, bipolar type. Participants were cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sung-Wan, Dodd, Seetal, Berk, Lesley, Kulkarni, Jayashri, de Castella, Anthony, Fitzgerald, Paul B., Kim, Jae-Min, Yoon, Jin-Sang, Berk, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504917/ https://www.ncbi.nlm.nih.gov/pubmed/26207128 http://dx.doi.org/10.4306/pi.2015.12.3.349

Ejemplares similares

Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
por: Kulkarni, Jayashri, et al.
Publicado: (2012)

Evaluation of the acceptability and usefulness of an information website for caregivers of people with bipolar disorder
por: Berk, Lesley, et al.
Publicado: (2013)

Tobacco Use in Bipolar Disorder
por: Thomson, Daniel, et al.
Publicado: (2015)

Evaluating discussion board engagement in the MoodSwings online self-help program for bipolar disorder: protocol for an observational prospective cohort study
por: Gliddon, Emma, et al.
Publicado: (2015)

Online ethics: where will the interface of mental health and the internet lead us?
por: Cosgrove, Victoria, et al.
Publicado: (2017)

Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0
por: Salagre, Estela, et al.
Publicado: (2018)

A Misdiagnosed Case of Schizoaffective Disorder With Bipolar Manifestations
por: Paul, Tanya, et al.
Publicado: (2021)

Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia
por: Cosgrove, Victoria E, et al.
Publicado: (2013)

Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression
por: Russell, Samantha E., et al.
Publicado: (2022)

Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated?
por: Mattingley, David William, et al.
Publicado: (2015)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial
por: Arancini, Lauren, et al.
Publicado: (2019)

Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
por: Dodd, Seetal, et al.
Publicado: (2015)

Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2013)

Socio-demographic, clinical and therapeutic features of patients treated for schizoaffective disorder using cannabis
por: Bouali, W., et al.
Publicado: (2023)

Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept
por: Hamshere, M. L., et al.
Publicado: (2009)

A brief review of exercise, bipolar disorder, and mechanistic pathways
por: Thomson, Daniel, et al.
Publicado: (2015)

Does Post-traumatic Stress Disorder Impact Treatment Outcomes within a Randomised Controlled Trial of Mitochondrial Agents for Bipolar Depression?
por: Russell, Samantha E., et al.
Publicado: (2023)

Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders
por: Dodd, Seetal, et al.
Publicado: (2022)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Listening to the silent struggles of bipolar disorder through sonification of iMoodJournal data
por: Angeler, David G., et al.
Publicado: (2022)

Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia
por: Studentkowski, G, et al.
Publicado: (2010)

Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study
por: Benedetti, Alessandra, et al.
Publicado: (2010)

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study
por: Carpiniello, Bernardo, et al.
Publicado: (2012)

A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
por: Berk, Michael, et al.
Publicado: (2019)

Staging in bipolar disorder: one step closer to precision psychiatry
por: Fernandes, Brisa S., et al.
Publicado: (2017)

Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
por: Berk, Michael, et al.
Publicado: (2012)

Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2015)

Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
por: Berk, Michael, et al.
Publicado: (2019)

The role of lamotrigine in the management of bipolar disorder
por: Ng, Felicity, et al.
Publicado: (2007)

Cost-Utility and Cost-effectiveness of MoodSwings 2.0, an Internet-Based Self-management Program for Bipolar Disorder: Economic Evaluation Alongside a Randomized Controlled Trial
por: Chatterton, Mary Lou, et al.
Publicado: (2022)

S189. CARVING A MORE SPECIFIC SUBTYPE OF SCHIZOPHRENIA FOR GENETIC STUDIES: SPORADIC SCHIZOAFFECTIVE BIPOLAR TYPE
por: van der Merwe, Nicolaas, et al.
Publicado: (2018)

Fusing Data Mining, Machine Learning and Traditional Statistics to Detect Biomarkers Associated with Depression
por: Dipnall, Joanna F., et al.
Publicado: (2016)

Into the Bowels of Depression: Unravelling Medical Symptoms Associated with Depression by Applying Machine-Learning Techniques to a Community Based Population Sample
por: Dipnall, Joanna F., et al.
Publicado: (2016)

Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders
por: Sethi, Rickinder, et al.
Publicado: (2019)

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia
por: Ashton, Melanie M., et al.
Publicado: (2019)

Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia
por: Ghanizadeh, Ahmad, et al.
Publicado: (2013)

Psychopathological Features of Bipolar Depression: Italian Validation of the Bipolar Depression Rating Scale (I-BDRS)
por: Bruschi, Angelo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c8q3li2iipl3g0as27lmgnm0fm